Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply

by Zacks Equity Research Published on January 03,2019

Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.

• MYGN Quick QuoteMYGNPositive Net Change
• EDIT Quick QuoteEDITNegative Net Change
• SRPT Quick QuoteSRPTNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

• biotechs

New Strong Sell Stocks for December 19th

by Zacks Equity Research Published on December 19,2018

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

• JOUT Quick QuoteJOUTNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change
• VST Quick QuoteVSTPositive Net Change
• SGPYY Quick QuoteSGPYYPositive Net Change

• oil-energy

Catalent (CTLT) Catches Eye: Stock Jumps 5.2%

by Zacks Equity Research Published on July 26,2018

Catalent (CTLT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

• CTLT Quick QuoteCTLTNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Zogenix's Epilepsy Candidate Successful in Phase III Study

by Zacks Equity Research Published on July 13,2018

Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.

• SMMT Quick QuoteSMMTNegative Net Change

Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%

by Zacks Equity Research Published on July 11,2018

Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

• IONS Quick QuoteIONSNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

KemPharm Stock Down Despite Positive Data on ADHD Candidate

by Zacks Equity Research Published on July 10,2018

KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.

• TARO Quick QuoteTARONegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Summit Therapeutics Enters Oversold Territory

by Zacks Equity Research Published on July 10,2018

Summit Therapeutics Enters Oversold Territory

• SMMT Quick QuoteSMMTNegative Net Change

What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

by Zacks Equity Research Published on May 14,2018

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

• PFE Quick QuotePFEPositive Net Change
• MKGAF Quick QuoteMKGAFNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

M&A, Innovation & New Drugs to Drive Pharma Stocks

by Zacks Equity Research Published on March 08,2018

The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.

• SMMT Quick QuoteSMMTNegative Net Change
• ZTS Quick QuoteZTSNegative Net Change

Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session

by Zacks Equity Research Published on February 21,2018

Shares of Apricus Biosciences (APRI) rose about 9% yesterday.

• SMMT Quick QuoteSMMTNegative Net Change

Sarepta's Golodirsen Positive in DMD Study, Shares Soar

by Zacks Equity Research Published on September 07,2017

Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

• BMRN Quick QuoteBMRNPositive Net Change
• SRPT Quick QuoteSRPTNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer

by Zacks Equity Research Published on August 18,2017

Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.

• ACAD Quick QuoteACADPositive Net Change
• JAZZ Quick QuoteJAZZNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised

by Zacks Equity Research Published on August 10,2017

Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.

• PRGO Quick QuotePRGOPositive Net Change
• ENZ Quick QuoteENZPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact

by Zacks Equity Research Published on August 09,2017

Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.

• ENZ Quick QuoteENZPositive Net Change
• JAZZ Quick QuoteJAZZNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress

by Zacks Equity Research Published on August 09,2017

Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.

• ENZ Quick QuoteENZPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss

by Zacks Equity Research Published on August 09,2017

Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.

• ENZ Quick QuoteENZPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

by Zacks Equity Research Published on August 09,2017

Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.

• JNJ Quick QuoteJNJPositive Net Change
• ENZ Quick QuoteENZPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View

by Zacks Equity Research Published on August 08,2017

Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.

• ALNY Quick QuoteALNYPositive Net Change
• ZTS Quick QuoteZTSNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered

by Zacks Equity Research Published on August 08,2017

Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.

• ALNY Quick QuoteALNYPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected

by Zacks Equity Research Published on August 08,2017

Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.

• ALNY Quick QuoteALNYPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

by Zacks Equity Research Published on August 04,2017

Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

• AZN Quick QuoteAZNPositive Net Change
• IRWD Quick QuoteIRWDNo Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

by Zacks Equity Research Published on August 04,2017

Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

• SMMT Quick QuoteSMMTNegative Net Change

Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

by Zacks Equity Research Published on August 04,2017

Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

• SMMT Quick QuoteSMMTNegative Net Change

Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy

by Zacks Equity Research Published on July 25,2017

Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy

• SMMT Quick QuoteSMMTNegative Net Change
• CVGI Quick QuoteCVGIPositive Net Change

Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

by Zacks Equity Research Published on July 20,2017

Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

• VRTX Quick QuoteVRTXPositive Net Change
• BMRN Quick QuoteBMRNPositive Net Change
• SRPT Quick QuoteSRPTNegative Net Change
• SMMT Quick QuoteSMMTNegative Net Change